FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA) has garnered significant interest as a therapeutic target in prostate cancer, especially following the approval of [177Lu]Lu-PSMA-617 (Pluvicto; Novartis) for the treatment of metastatic castration-resistant prostate cancer (9).